Evaluation of the Performance and Safety of the Atoldys/ Lexilens Glasses Developed to Improve the Reading of Dyslexic Subjects

Dyslexia Clinical Trial

Official title:

Evaluation of the Performance and Safety of the Atoldys/ Lexilens Glasses Developed to Improve the Reading of Dyslexic Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04586621
• Other study ID #: Atoldys/ Lexilens
• Status: Completed
• Phase: N/A
• Start date: January 19, 2021
• Est. completion date: June 29, 2021

Study information

• Verified date: February 2022
• Source: ABEYE
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to evaluate the efficacy and safety of a new medical device (Atoldys/ Lexilens glasses) on the improvement of reading skills of young dyslexic subjects.

Description:

Dyslexia is defined as a specific learning disability that is characterized by reading difficulties, in the absence of intellectual disability, neurological or psychiatric disorder, uncorrected sensory disturbance (sight, hearing) or an educational deficiency.

Dyslexia appears in the child from the earliest stages of learning in the form of a difficulty in mastering the learning of reading. This disorder is manifested by a generally hesitant reading, slowed down, full of errors, requiring a lot of effort for the child and may impact his reading comprehension. The dyslexia-related deficiency is of variable intensity depending on the individual; it may be accompanied by calculus disorders (dyscalculia), oral language (dysphasia), motor coordination (dyspraxia) or attention disorders with or without hyperactivity. In nearly 40% of cases, a child affected by Dys disorders presents several learning disorders.

To date, the causes of dyslexia are not yet clearly established. The wide variety of symptoms and disorders associated with dyslexia does not facilitate the identification of precise neurobiological / psycho cognitive mechanisms. There are therefore several theories: phonological, visual, temporal, cerebellar or proprioceptive auditory processing.

Recently, following work published in 2017, an anatomical cause based on Maxwell's spots could also be a cause of dyslexia.

The aim of this study is to evaluate a new medical device (class I CE marked) to compensate this probable anatomical cause: the Atoldys/ Lexilens glasses

Recruitment information / eligibility

• Status: Completed
• Enrollment: 41
• Est. completion date: June 29, 2021
• Est. primary completion date: June 29, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 8 Years to 13 Years

Eligibility

Inclusion Criteria:

• Schooled in CM1, CM2 or 6ème,

• French mother tongue,

• For whom developmental dyslexia has been diagnosed by a health professional who specializes in this learning disorder,

• With near vision, without optical correction, equivalent to P5 or better according to the Parinaud scale (distance: 30-40 cm),

• Presenting an IQ = 80 and =130 according to the WISC-V test performed by a psychologist,

• For whom a written consent was obtained regarding his study participation.

Exclusion Criteria:

• With medical history or presenting a neurological pathology,

• Presenting a developmental disorder (autism, ADHD, ...),

• Presenting hearing disorders,

• Presenting an astigmatism of more than one uncorrected diopter,

• Presenting other visual disorders,

• Any other condition that, in the opinion of health professionals, could impair its ability to complete the study or could pose a significant risk.

Related Conditions & MeSH terms

• Dyslexia

Intervention

Device:
• Atoldys/ Lexilens - SHAM
Atoldys/ Lexilens: glasses with specific light frequency SHAM: glasses with no frequency
• SHAM- Atoldys/ Lexilens
SHAM: glasses with no frequency Atoldys/ Lexilens: glasses with specific light frequency

Locations

Country	Name	City	State
France	Dr Laurence Derieux	Caen
France	Dr Luc-Marie Virlet	Faumont
France	CHU Rennes	Rennes

Sponsors (2)

Lead Sponsor	Collaborator
ABEYE	Slb Pharma

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Reading performance aloud of a text with french E.L.FE Test	E.L.FE Test (=Evaluation de la Lecture en FluencE) - "Monsieur Petit" and "Le Géant égoïste" texts : percentile	1 day
Secondary	Reading performance aloud of isolated words with french BALE Test	BALE test (=Batterie Analytique de Langage Ecrit): percentile	1 day
Secondary	Security: incidence of Adverse Events	By questioning the child & the speech therapist - evaluation of adverse effects due to glasses (Yes/ No): headache, nausea, dizziness, fatigue and eye fatigue. According to patient questioning and clinical exam, the Adverse Event Table will be completed (description, dates, severity, imputability, action,...).	1 day
Secondary	Security: device deficiencies	By questioning the speech therapist - evaluation of deficiencies due to glasses: the device deficienciesTable will be completed (description, relation with adverse effect, taken measures,...).	1 day
Secondary	Child's satisfaction regarding reading fluency and comprehension	Child interview with numeric scale (0-10) and yes/ no answer	1 day
Secondary	Speech therapist's satisfaction regarding Securirty, Performance and Usability of glasses	speech therapist interview with 4 points - Likert scale (Very good, Good, Moderate, Bad)	1 day